Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 1
1987 6
1988 1
1989 5
1990 2
1991 11
1992 6
1993 12
1994 15
1995 20
1996 18
1997 14
1998 17
1999 18
2000 18
2001 21
2002 14
2003 17
2004 25
2005 28
2006 29
2007 31
2008 37
2009 35
2010 27
2011 25
2012 28
2013 31
2014 16
2015 11
2016 9
2017 13
2018 15
2019 4
2020 11
2021 12
2022 12
2023 9
2024 17
2025 10
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

601 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
Heart Outcomes Prevention Evaluation Study Investigators; Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Heart Outcomes Prevention Evaluation Study Investigators, et al. N Engl J Med. 2000 Jan 20;342(3):145-53. doi: 10.1056/NEJM200001203420301. N Engl J Med. 2000. PMID: 10639539 Free article. Clinical Trial.
We assessed the role of an angiotensin-converting-enzyme inhibitor, ramipril, in patients who were at high risk for cardiovascular events but who did not have left ventricular dysfunction or heart failure. ...The trial was a two-by-two factorial study evaluating both ra …
We assessed the role of an angiotensin-converting-enzyme inhibitor, ramipril, in patients who were at high risk for cardiovascular ev …
Ramipril After Transcatheter Aortic Valve Implantation in Patients Without Reduced Ejection Fraction: The RASTAVI Randomized Clinical Trial.
Amat-Santos IJ, López-Otero D, Nombela-Franco L, Peral-Disdier V, Gutiérrez-Ibañes E, Jiménez-Diaz V, Muñoz-Garcia A, Del Valle R, Regueiro A, Ibáñez B, Romaguera R, Cuellas Ramón C, García B, Sánchez PL, Gómez-Herrero J, Gonzalez-Juanatey JR, Tirado-Conte G, Fernández-Avilés F, Raposeiras-Roubin S, Revilla-Orodea A, López-Diaz J, Gómez I, Carrasco-Moraleja M, San Román JA. Amat-Santos IJ, et al. J Am Heart Assoc. 2024 Oct;13(19):e035460. doi: 10.1161/JAHA.124.035460. Epub 2024 Sep 18. J Am Heart Assoc. 2024. PMID: 39291483 Free PMC article. Clinical Trial.
Renin-angiotensin system inhibitors may be beneficial in this setting. We aimed to explore whether ramipril improves the outcomes of patients with aortic stenosis after transcatheter aortic valve implantation. ...The primary end point occurred in 10.6% in the ramipril …
Renin-angiotensin system inhibitors may be beneficial in this setting. We aimed to explore whether ramipril improves the outcomes of …
Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients.
Anderson VR, Perry CM, Robinson DM. Anderson VR, et al. Am J Cardiovasc Drugs. 2006;6(6):417-32. doi: 10.2165/00129784-200606060-00012. Am J Cardiovasc Drugs. 2006. PMID: 17192135 Review.
Ramipril is an oral, non-sulfhydryl ACE inhibitor thought to act in the renin-angiotensin-aldosterone system to decrease vasopressor activity, aldosterone secretion, and bradykinin degradation. ...Thus, ramipril, in addition to lifestyle interventions, should be con …
Ramipril is an oral, non-sulfhydryl ACE inhibitor thought to act in the renin-angiotensin-aldosterone system to decrease vasopressor …
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.
Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, Mann DL, McMurray JJV, Rouleau JL, Solomon SD, Steg PG, Berwanger O, Cikes M, De Pasquale CG, East C, Fernandez A, Jering K, Landmesser U, Mehran R, Merkely B, Vaghaiwalla Mody F, Petrie MC, Petrov I, Schou M, Senni M, Sim D, van der Meer P, Lefkowitz M, Zhou Y, Gong J, Braunwald E; PARADISE-MI Investigators and Committees. Pfeffer MA, et al. N Engl J Med. 2021 Nov 11;385(20):1845-1855. doi: 10.1056/NEJMoa2104508. N Engl J Med. 2021. PMID: 34758252 Clinical Trial.
RESULTS: A total of 5661 patients underwent randomization; 2830 were assigned to receive sacubitril-valsartan and 2831 to receive ramipril. Over a median of 22 months, a primary-outcome event occurred in 338 patients (11.9%) in the sacubitril-valsartan group and in 373 pat …
RESULTS: A total of 5661 patients underwent randomization; 2830 were assigned to receive sacubitril-valsartan and 2831 to receive ramipri …
Ramipril for the Treatment of COVID-19: RAMIC, a Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Huang DQ, Ajmera V, Tomaszewski C, LaFree A, Bettencourt R, Thompson WK, Smith DM, Malhotra A, Mehta RL, Tolia V, Yin J, Insel PA, Leachman S, Jung J, Collier S, Richards L, Woods K, Amangurbanova M, Bhatt A, Zhang X, Penciu OM, Zarich S, Retta T, Harkins MS, Teixeira JP, Chinnock B, Utay NS, Lake JE, Loomba R. Huang DQ, et al. Adv Ther. 2023 Nov;40(11):4805-4816. doi: 10.1007/s12325-023-02618-7. Epub 2023 Aug 24. Adv Ther. 2023. PMID: 37615850 Free PMC article. Clinical Trial.
Participants were randomly assigned to daily ramipril 2.5 mg or placebo orally in a 2:1 ratio, using permuted block randomization. Analyses were conducted on an intention-to-treat basis. ...Two participants in the ramipril group required ICU admission and one died, …
Participants were randomly assigned to daily ramipril 2.5 mg or placebo orally in a 2:1 ratio, using permuted block randomization. An …
Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis: The ARCADIA Multicenter Randomized Controlled Trial.
Ruggenenti P, Podestà MA, Trillini M, Perna A, Peracchi T, Rubis N, Villa D, Martinetti D, Cortinovis M, Ondei P, Condemi CG, Guastoni CM, Meterangelis A, Granata A, Mambelli E, Pasquali S, Genovesi S, Pieruzzi F, Bertoli SV, Del Rosso G, Garozzo M, Rigotti A, Pozzi C, David S, Daidone G, Mingardi G, Mosconi G, Galfré A, Romei Longhena G, Pacitti A, Pani A, Hidalgo Godoy J, Anders HJ, Remuzzi G; ARCADIA Study Organization. Ruggenenti P, et al. Clin J Am Soc Nephrol. 2021 Apr 7;16(4):575-587. doi: 10.2215/CJN.12940820. Epub 2021 Mar 29. Clin J Am Soc Nephrol. 2021. PMID: 33782036 Free PMC article. Clinical Trial.
Hypotensive episodes were more frequent in participants allocated to ramipril than controls (41% versus 12%). Twenty participants on ramipril and nine controls developed cancer, including six gastrointestinal malignancies on ramipril (four were fatal), compar …
Hypotensive episodes were more frequent in participants allocated to ramipril than controls (41% versus 12%). Twenty participants on …
Comparison of the effectiveness of aliskiren and ramipril for the management of hypertension: A systematic review and meta-analysis.
Alam T, Asif Ansari M. Alam T, et al. Hipertens Riesgo Vasc. 2025 Apr-Jun;42(2):94-101. doi: 10.1016/j.hipert.2024.11.002. Epub 2024 Dec 10. Hipertens Riesgo Vasc. 2025. PMID: 39665939
OBJECTIVE: Ramipril is an important option in the management of hypertension, while the role of aliskiren is still up for debate. ...RCTs that included hypertensive patients who were under either aliskiren or ramipril treatment were included in the analysis. The ris …
OBJECTIVE: Ramipril is an important option in the management of hypertension, while the role of aliskiren is still up for debate. ... …
Ramipril and the development of diabetes.
Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B; HOPE Study Investigators. Yusuf S, et al. JAMA. 2001 Oct 17;286(15):1882-5. doi: 10.1001/jama.286.15.1882. JAMA. 2001. PMID: 11597291 Clinical Trial.
OBJECTIVE: To investigate the effectiveness of ramipril, an angiotensin-converting enzyme inhibitor, in preventing diabetes among high-risk persons. ...These effects were also consistently seen in several subgroups examined. CONCLUSIONS: Ramipril is associated with …
OBJECTIVE: To investigate the effectiveness of ramipril, an angiotensin-converting enzyme inhibitor, in preventing diabetes among hig …
Impediment of the progressions of microalbuminuria and hyperlipidemia in normotensive type 2 diabetes by low-dose ramipril.
Vongterapak S, Dahlan W, Nakasatien S, Anuntakulnatee T, Suppanich M, Kittipoom W, Surasingchaidet C, Tamwiwat C, Tepkasetkul M, Bunnag P, Ongphiphadhanakul B, Rajatanavin R, Himathongkam T. Vongterapak S, et al. J Med Assoc Thai. 1998 Sep;81(9):671-81. J Med Assoc Thai. 1998. PMID: 9737124 Review.
During a 3 month period, increased urine albumin excretion was observed in normotensive type 2 diabetes with microalbuminuria who received only placebo. We conclude that ramipril may arrest the progression of albumin excretion and had favorable effects on serum lipids. …
During a 3 month period, increased urine albumin excretion was observed in normotensive type 2 diabetes with microalbuminuria who received o …
Ramipril Improves Endothelial Function and Increases the Number of Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus.
Oliveira ACD, Arismendi MI, Machado LSG, Sato EI. Oliveira ACD, et al. J Clin Rheumatol. 2022 Oct 1;28(7):349-353. doi: 10.1097/RHU.0000000000001869. Epub 2022 Jun 8. J Clin Rheumatol. 2022. PMID: 35662232 Clinical Trial.
METHODS: This was a randomized trial including 37 female SLE patients without cardiovascular risk factors allocated into 2 groups: 19 patients received ramipril 10 mg/d for 12 weeks (IG) and 18 patients maintained without ramipril (CG). Endothelial function was asse …
METHODS: This was a randomized trial including 37 female SLE patients without cardiovascular risk factors allocated into 2 groups: 19 patien …
601 results